WNK2 and melanoma: One of the most recent options for melanoma treatment is targeted therapy, being the combination of BRAF (V-RAF murine sarcoma viral oncogene homolog B) and MEK (mitogen-activated protein kinase kinase) inhibitors used to enhance survival in BRAF-mutated patients [6,7,8].